HI
IONS icon

Horizon Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Horizon Investments’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06K Sell
26
-22
-46% -$1.66K ﹤0.01% 1267
2026
Q1 		$3.6K Buy
48
+26
+118% +$2.05K ﹤0.01% 1245
2025
Q4 		$1.74K Hold
22
– – ﹤0.01% 1213
2025
Q3 		$1.44K Buy
22
+7
+47% +$342 ﹤0.01% 1103
2025
Q2 		$593 Buy
+15
New +$491 ﹤0.01% 1070
2025
Q1 		– Sell
-1,174
Closed -$41K – 900
2024
Q4 		$41K Buy
1,174
+73
+7% +$2.73K ﹤0.01% 651
2024
Q3 		$44.1K Sell
1,101
-393
-26% -$18.3K ﹤0.01% 639
2024
Q2 		$71.2K Sell
1,494
-853
-36% -$35K ﹤0.01% 630
2024
Q1 		$102K Buy
2,347
+420
+22% +$20K ﹤0.01% 613
2023
Q4 		$97.5K Buy
1,927
+28
+1% +$1.34K ﹤0.01% 599
2023
Q3 		$86.1K Buy
1,899
+163
+9% +$6.72K ﹤0.01% 617
2023
Q2 		$71.2K Buy
1,736
+397
+30% +$15.3K ﹤0.01% 614
2023
Q1 		$47.9K Buy
+1,339
New +$50.3K ﹤0.01% 619

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Horizon Investments's IONS Position: Q2 2026 in Review

Horizon Investments reduced its Ionis Pharmaceuticals (IONS) stake by 46% in Q2 2026, selling an estimated $1.66K and leaving 26 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

Horizon Investments first reported a position in IONS in Q1 2023 and has held it in 13 quarters since. The position peaked at $102K in Q1 2024. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Horizon Investments held 26 shares of Ionis Pharmaceuticals worth $2.06K as of Q2 2026.
  • Horizon Investments sold 22 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.66K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Horizon Investments's portfolio in Q2 2026, its #1267 holding.
  • Horizon Investments first reported a position in Ionis Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Horizon Investments's Ionis Pharmaceuticals position peaked at $102K in Q1 2024.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.